Drug Information Association (DIA) Annual Meeting

"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants.

Jaydev Thakkar, chief operating officer, Biofourmis discusses how Biofourmis got involved with the CancerX Initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis discusses the work his organization is doing within the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Jaydev Thakkar, chief operating officer, Biofourmis gives an overview of the CancerX initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of the EFGCP eConsent Initiative at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders gives an overview of eConsent at the 2023 DIA annual meeting in Boston, MA.

Hilde Vanaken, PhD, head, European Forum GCP (EFGCP) eConsent Initiative, and head, TCS Industry Leaders discusses takeaways from a 2023 DIA session she spoke at on eConsent.

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved.

CDER and CBER leaders update initiatives in the rare disease space within the past year.

Emily Botto, research analyst, Tufts CSDD speaks about a recent study on the impact of exclusionary behaviors on team dynamics conducted by Tufts at the 2023 DIA annual meeting in Boston, MA.

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about returning patient data at the 2023 DIA annual meeting in Boston, MA.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Venkatraman Balasubramanian, SVP and global head, industry solutions, healthcare and life sciences, Orion Innovation, discusses feedback from the audience during his session, “The Case for Generating Synthetic Data as Real-World Data: Regulatory and Planning Perspectives.”

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about keeping patients informed at the 2023 DIA annual meeting in Boston, MA.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Venkatraman Balasubramanian, SVP and global head, industry solutions, healthcare and life sciences, Orion Innovation, provides a synopsis of "“The Case for Generating Synthetic Data as Real-World Data: Regulatory and Planning Perspectives.”

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about giving patients more power in decision making at the 2023 DIA annual meeting in Boston, MA.

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

Panel explores challenges that could affect their development.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses issues that will be addressed at the upcoming FDA town hall.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses analyzing AI in Regulatory Decision Making

DIA session focuses on the ins and outs of returning individual participant data.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.

Session explores practicality of models for selling low-cost drugs.

DIA session highlights strategies for stakeholders to make clinical trials more inclusive for diverse populations.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott, Senior Manager, Scientific Programs, Drug Information Association, discusses DIA educational opportunities improving clinical operations staff on DE&I concerns.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott,Senior Manager, Scientific Programs, Drug Information Association, discusses changes to the role of diversity in clinical trials in regard to scientific programing.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses the near-term and long-term future of SMART on FHIR.

Panel at DIA discussed the evolving role of pharmacies in clinical trials.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses his passion for SMART on FHIR.

Sponsors offers patient and caregiver insights on hybrid and decentralized clinical trial design provided by their feedback processes.